Last updated: 2026-09-21 04:19:40. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Parabilis Medicines, Inc. (PBLS) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $41,66, with a market capitalisation of $5,16B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $24,51 to $42,49. This page covers its latest market performance, valuation, price trends and company information.
$5,16B | |
$41,01 | |
$42,49 | |
$24,51 | |
$40,88 | |
1,16M | |
603,93K | |
-- | |
$42,49 | |
$24,51 | |
-- | |
-- |
Parabilis Medicines, Inc. (PBLS) last closed at $40,88 as of 2026-09-18 23:33:00, unchanged from the previous close of $40,88.
During the latest regular trading session, PBLS traded between $24,51 and $42,49, with a volume of 1,16M shares. The closing price was near the upper end and near the upper end of its 52-week range.
Over the past seven days, Parabilis Medicines, Inc. (PBLS) moved from $36,32 to $41,66, representing a gain of 14,71% ($5,34).
The stock traded between $35,24 and $42,49 during the period. The latest price is near the upper end of the 7-day range, indicating strong upward.
The average daily volume was 1,87 million shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 95,4%
PBLS is currently trading at $41,66, placing it 95,4% of the way from its 52-week low of $24,51 to its 52-week high of $42,49. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Parabilis Medicines Inc s a clinical-stage biopharmaceutical company. It is focused on the development of medicines targeting protein interactions associated with human diseases. It uses a proprietary platform to develop stabilized helical peptide therapeutics, referred to as Helicons, designed to bind and modulate specific proteins. Its flagship product candidate, zolucatetide, targets the interaction between β-catenin and the T-cell factor (TCF) family of transcription factors within the Wnt/β-catenin signaling pathway, which is associated with cell proliferation and differentiation in multiple cancer types.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Parabilis Medicines, Inc. (PBLS) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.